Shots:

• LogicBio to receive $10M up front with ~$581M as option payment and milestones along with royalties. Canbridge to get an exclusive option to license LB-001 in Greater China and two additional undisclosed gene therapy programs.
• The agreement also grants CANbridge a WW license for AAV sL65 which is the first capsid produced from LogicBio's sAAVy platform- and development support on gene therapy candidates for Fabry and Pompe disease + two optional indications
• Canbridge will responsible for the development- regulatory- commercial- and manufacturing activities in the licensed territory upon exercise of an option

  Ref: PRNewswire | Image: LogicBio